Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene
Identifieur interne : 000746 ( Pmc/Corpus ); précédent : 000745; suivant : 000747Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene
Auteurs : Attapon Kamlangdee ; Brock Kingstad-Bakke ; Tavis K. Anderson ; Tony L. Goldberg ; Jorge E. OsorioSource :
- Journal of Virology [ 0022-538X ] ; 2014.
Abstract
A critical failure in our preparedness for an influenza pandemic is the lack of a universal vaccine. Influenza virus strains diverge by 1 to 2% per year, and commercially available vaccines often do not elicit protection from one year to the next, necessitating frequent formulation changes. This represents a major challenge to the development of a cross-protective vaccine that can protect against circulating viral antigenic diversity. We have constructed a recombinant modified vaccinia virus Ankara (MVA) that expresses an H5N1 mosaic hemagglutinin (H5M) (MVA-H5M). This mosaic was generated
Url:
DOI: 10.1128/JVI.01532-14
PubMed: 25210173
PubMed Central: 4249068
Links to Exploration step
PMC:4249068Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene</title>
<author><name sortKey="Kamlangdee, Attapon" sort="Kamlangdee, Attapon" uniqKey="Kamlangdee A" first="Attapon" last="Kamlangdee">Attapon Kamlangdee</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kingstad Bakke, Brock" sort="Kingstad Bakke, Brock" uniqKey="Kingstad Bakke B" first="Brock" last="Kingstad-Bakke">Brock Kingstad-Bakke</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Anderson, Tavis K" sort="Anderson, Tavis K" uniqKey="Anderson T" first="Tavis K." last="Anderson">Tavis K. Anderson</name>
<affiliation><nlm:aff id="aff2">Department of Biology, Georgia Southern University, Statesboro, Georgia, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Goldberg, Tony L" sort="Goldberg, Tony L" uniqKey="Goldberg T" first="Tony L." last="Goldberg">Tony L. Goldberg</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Osorio, Jorge E" sort="Osorio, Jorge E" uniqKey="Osorio J" first="Jorge E." last="Osorio">Jorge E. Osorio</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25210173</idno>
<idno type="pmc">4249068</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249068</idno>
<idno type="RBID">PMC:4249068</idno>
<idno type="doi">10.1128/JVI.01532-14</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000746</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000746</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene</title>
<author><name sortKey="Kamlangdee, Attapon" sort="Kamlangdee, Attapon" uniqKey="Kamlangdee A" first="Attapon" last="Kamlangdee">Attapon Kamlangdee</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kingstad Bakke, Brock" sort="Kingstad Bakke, Brock" uniqKey="Kingstad Bakke B" first="Brock" last="Kingstad-Bakke">Brock Kingstad-Bakke</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Anderson, Tavis K" sort="Anderson, Tavis K" uniqKey="Anderson T" first="Tavis K." last="Anderson">Tavis K. Anderson</name>
<affiliation><nlm:aff id="aff2">Department of Biology, Georgia Southern University, Statesboro, Georgia, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Goldberg, Tony L" sort="Goldberg, Tony L" uniqKey="Goldberg T" first="Tony L." last="Goldberg">Tony L. Goldberg</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Osorio, Jorge E" sort="Osorio, Jorge E" uniqKey="Osorio J" first="Jorge E." last="Osorio">Jorge E. Osorio</name>
<affiliation><nlm:aff id="aff1">Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Virology</title>
<idno type="ISSN">0022-538X</idno>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>ABSTRACT</title>
<p>A critical failure in our preparedness for an influenza pandemic is the lack of a universal vaccine. Influenza virus strains diverge by 1 to 2% per year, and commercially available vaccines often do not elicit protection from one year to the next, necessitating frequent formulation changes. This represents a major challenge to the development of a cross-protective vaccine that can protect against circulating viral antigenic diversity. We have constructed a recombinant modified vaccinia virus Ankara (MVA) that expresses an H5N1 mosaic hemagglutinin (H5M) (MVA-H5M). This mosaic was generated <italic>in silico</italic>
using 2,145 field-sourced H5N1 isolates. A single dose of MVA-H5M provided 100% protection in mice against clade 0, 1, and 2 avian influenza viruses and also protected against seasonal H1N1 virus (A/Puerto Rico/8/34). It also provided short-term (10 days) and long-term (6 months) protection postvaccination. Both neutralizing antibodies and antigen-specific CD4<sup>+</sup>
and CD8<sup>+</sup>
T cells were still detected at 5 months postvaccination, suggesting that MVA-H5M provides long-lasting immunity.</p>
<p><bold>IMPORTANCE</bold>
Influenza viruses infect a billion people and cause up to 500,000 deaths every year. A major problem in combating influenza is the lack of broadly effective vaccines. One solution from the field of human immunodeficiency virus vaccinology involves a novel <italic>in silico</italic>
mosaic approach that has been shown to provide broad and robust protection against highly variable viruses. Unlike a consensus algorithm which picks the most frequent residue at each position, the mosaic method chooses the most frequent T-cell epitopes and combines them to form a synthetic antigen. These studies demonstrated that a mosaic influenza virus H5 hemagglutinin expressed by a viral vector can elicit full protection against diverse H5N1 challenges as well as induce broader immunity than a wild-type hemagglutinin.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Virol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Virol</journal-id>
<journal-id journal-id-type="hwp">jvi</journal-id>
<journal-id journal-id-type="pmc">jvi</journal-id>
<journal-id journal-id-type="publisher-id">JVI</journal-id>
<journal-title-group><journal-title>Journal of Virology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-538X</issn>
<issn pub-type="epub">1098-5514</issn>
<publisher><publisher-name>American Society for Microbiology</publisher-name>
<publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">25210173</article-id>
<article-id pub-id-type="pmc">4249068</article-id>
<article-id pub-id-type="publisher-id">01532-14</article-id>
<article-id pub-id-type="doi">10.1128/JVI.01532-14</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Vaccines and Antiviral Agents</subject>
</subj-group>
</article-categories>
<title-group><article-title>Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Kamlangdee</surname>
<given-names>Attapon</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kingstad-Bakke</surname>
<given-names>Brock</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Anderson</surname>
<given-names>Tavis K.</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Goldberg</surname>
<given-names>Tony L.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Osorio</surname>
<given-names>Jorge E.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<aff id="aff1"><label>a</label>
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA</aff>
<aff id="aff2"><label>b</label>
Department of Biology, Georgia Southern University, Statesboro, Georgia, USA</aff>
</contrib-group>
<contrib-group><contrib contrib-type="editor"><name><surname>Lyles</surname>
<given-names>D. S.</given-names>
</name>
<role>Editor</role>
</contrib>
</contrib-group>
<author-notes><corresp id="cor1">Address correspondence to Jorge E. Osorio, <email>osorio@svm.vetmed.wisc.edu</email>
.</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>11</month>
<year>2014</year>
</pub-date>
<volume>88</volume>
<issue>22</issue>
<fpage>13300</fpage>
<lpage>13309</lpage>
<history><date date-type="received"><day>29</day>
<month>5</month>
<year>2014</year>
</date>
<date date-type="accepted"><day>26</day>
<month>8</month>
<year>2014</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</copyright-statement>
<copyright-year>2014</copyright-year>
<copyright-holder>American Society for Microbiology</copyright-holder>
</permissions>
<self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zjv02214013300.pdf"></self-uri>
<abstract><title>ABSTRACT</title>
<p>A critical failure in our preparedness for an influenza pandemic is the lack of a universal vaccine. Influenza virus strains diverge by 1 to 2% per year, and commercially available vaccines often do not elicit protection from one year to the next, necessitating frequent formulation changes. This represents a major challenge to the development of a cross-protective vaccine that can protect against circulating viral antigenic diversity. We have constructed a recombinant modified vaccinia virus Ankara (MVA) that expresses an H5N1 mosaic hemagglutinin (H5M) (MVA-H5M). This mosaic was generated <italic>in silico</italic>
using 2,145 field-sourced H5N1 isolates. A single dose of MVA-H5M provided 100% protection in mice against clade 0, 1, and 2 avian influenza viruses and also protected against seasonal H1N1 virus (A/Puerto Rico/8/34). It also provided short-term (10 days) and long-term (6 months) protection postvaccination. Both neutralizing antibodies and antigen-specific CD4<sup>+</sup>
and CD8<sup>+</sup>
T cells were still detected at 5 months postvaccination, suggesting that MVA-H5M provides long-lasting immunity.</p>
<p><bold>IMPORTANCE</bold>
Influenza viruses infect a billion people and cause up to 500,000 deaths every year. A major problem in combating influenza is the lack of broadly effective vaccines. One solution from the field of human immunodeficiency virus vaccinology involves a novel <italic>in silico</italic>
mosaic approach that has been shown to provide broad and robust protection against highly variable viruses. Unlike a consensus algorithm which picks the most frequent residue at each position, the mosaic method chooses the most frequent T-cell epitopes and combines them to form a synthetic antigen. These studies demonstrated that a mosaic influenza virus H5 hemagglutinin expressed by a viral vector can elicit full protection against diverse H5N1 challenges as well as induce broader immunity than a wild-type hemagglutinin.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000746 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000746 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Pmc |étape= Corpus |type= RBID |clé= PMC:4249068 |texte= Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:25210173" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
This area was generated with Dilib version V0.6.34. |